Regulus Therapeutics (NASDAQ:RGLS) Given “Buy” Rating at HC Wainwright

Regulus Therapeutics (NASDAQ:RGLS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $9.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 303.59% from the stock’s current price.

Several other research analysts have also recently issued reports on RGLS. Leerink Partnrs restated an “outperform” rating on shares of Regulus Therapeutics in a report on Monday, March 18th. SVB Leerink began coverage on Regulus Therapeutics in a research report on Monday, March 18th. They set an “outperform” rating and a $6.00 price target on the stock. Canaccord Genuity Group reduced their price objective on Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, March 19th. Wells Fargo & Company raised their target price on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 13th. Finally, StockNews.com assumed coverage on shares of Regulus Therapeutics in a research report on Tuesday, April 16th. They set a “sell” rating on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Regulus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

Regulus Therapeutics Stock Down 8.2 %

NASDAQ RGLS opened at $2.23 on Monday. Regulus Therapeutics has a 52 week low of $1.08 and a 52 week high of $3.79. The stock has a market capitalization of $145.98 million, a PE ratio of -1.40 and a beta of 1.59. The firm has a 50 day moving average of $2.34 and a two-hundred day moving average of $1.69.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.40). On average, equities research analysts expect that Regulus Therapeutics will post -0.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Regulus Therapeutics

A number of hedge funds have recently modified their holdings of RGLS. Victory Capital Management Inc. grew its position in shares of Regulus Therapeutics by 5.3% during the third quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company’s stock worth $322,000 after acquiring an additional 11,701 shares during the last quarter. FMR LLC raised its position in Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock worth $4,033,000 after buying an additional 716,000 shares during the last quarter. Vivo Capital LLC acquired a new stake in shares of Regulus Therapeutics in the 1st quarter worth $14,400,000. Finally, CVI Holdings LLC acquired a new stake in shares of Regulus Therapeutics in the 1st quarter worth $4,050,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.